Letter to the editor commenting on the published phase 2 retatrutide clinical trial for obesity. Raises a specific question, observation, or concern about the trial's findings, methodology, or implications—one of multiple correspondence pieces published in response to the landmark retatrutide results showing ~24% weight loss.
Elfeki, Mohamed A; Alkhouri, Naim